Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-659 + tezacaftor + VX-561
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**VX-659 + tezacaftor + VX-561** is a triple combination investigational therapy for cystic fibrosis (CF), comprising two CFTR correctors (VX-659 and tezacaftor) and one CFTR potentiator (VX-561, a once-daily deuterated ivacaftor). VX-659 and tezacaftor act on different sites of the CFTR protein, improving its processing and trafficking to the cell surface, while VX-561 facilitates the sustained opening of the chloride channel, thus enhancing chloride and sodium ion transport across epithelial surfaces. This combination targets the underlying protein defect in CF caused by Phe508del mutations, and has shown additive clinical efficacy in lung function and sweat chloride reduction, with a safety profile similar to dual combination CFTR modulators. Developed by Vertex Pharmaceuticals, the regimen is intended to treat CF patients with both Phe508del/Phe508del and Phe508del/minimal function genotypes[1][2][3][4].
- Other names
- VX-659 + tezacaftor + VX-561
02
Targets
CFTR (Cystic fibrosis transmembrane conductance regulator)
Beyond the preview
Go deeper on VX-659 + tezacaftor + VX-561.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-659 + tezacaftor + VX-561.